Sugi Predict

Sugi Predict / Compounds / SCHEMBL3948673

SCHEMBL3948673

SCHEMBL3948673

O=C(O)C(S)C(=S)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA3 P07451 1/20 0.44
▸ CA4 P22748 1/20 0.44
▸ CA6 P23280 1/20 0.44
▸ CA5A P35218 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ CA13 Q8N1Q1 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ CA5B Q9Y2D0 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ TSHR P16473 4/20 0.42
▸ CES1 P23141 3/20 0.42
▸ CES2 O00748 2/20 0.42
▸ DAO P14920 1/20 0.42
▸ NAPRT Q6XQN6 1/20 0.42
▸ TP53 P04637 1/20 0.41
▸ TDP1 Q9NUW8 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10530602 1.00 CA12 (0.44) CA12CA1CA2CA3CA4
SCHEMBL3048237 0.79 KMT2A (0.49) ALDH1A1TSHRCES1CES2TDP1
SCHEMBL5274104 0.77 TDP1 (0.52) CA12CA1CA2CA3CA4
SCHEMBL7207824 0.77 TDP1 (0.52) CA12CA1CA2CA3CA4
SCHEMBL3948669 0.77 CA12 (0.48) CA12CA1CA2CA3CA4
SCHEMBL2171281 0.77 CA12 (0.48) CA12CA1CA2CA3CA4
SCHEMBL4231267 0.76 NPC1 (0.53) ALDH1A1TSHRTDP1MAPTPOLB
SCHEMBL28361421 0.74 ALDH1A1 (0.48) CA12CA1CA2CA3CA4
SCHEMBL28178715 0.74 MAPT (0.48) ALDH1A1TSHRCES1CES2DAO
SCHEMBL5664534 0.73 ALDH1A1 (0.38) CA12CA1CA2CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119591812-A Heat-resistant AMSAN resin with double-layer structure and preparation method and application thereof 万华化学集团股份有限公司 2025-03-11 — — CN disclosed
WO-2009073147-A2 PROCESS FOR PREPARING BIS(THIOHYDRAZIDE AMIDES) SYNTA PHARMACEUTICALS CORP. (US) 2009-06-11 — — WO disclosed
US-7402690-B2 Chain transfer agents for raft polymerization in aqueous media UNIVERSITY OF SOUTHERN MISSISSIPPI (US) 2008-07-22 — — US disclosed
US-20070123670-A1 Chain transfer agents for raft polymerization in aqueous media MCCORMICK CHARLES L 2007-05-31 — — US disclosed
US-7205362-B2 Method for controlled radical polymerization bioMérieux (FR) 2007-04-17 — — US disclosed
US-20070073011-A1 Method for controlled radical polymerization BIOMERIEUX (FR) 2007-03-29 — — US disclosed
US-7186786-B2 Chain transfer agents for RAFT polymerization in aqueous media UNIVERSITY OF SOUTHERN MISSISSIPPI (US) 2007-03-06 — — US disclosed
US-7179872-B2 Chain transfer agents for RAFT polymerization in aqueous media UNIVERSITY OF SOUTHERN MISSISSIPPI (US) 2007-02-20 — — US disclosed
US-20060111531-A1 Chain transfer agents for RAFT polymerization in aqueous media UNIVERSITY OF SOUTHERN MISSISSIPPI 2006-05-25 — — US disclosed
US-20060111532-A1 Chain transfer agents for RAFT polymerization in aqueous media UNIVERSITY OF SOUTHERN MISSISSIPPI 2006-05-25 — — US disclosed
US-20030195310-A1 Chain transfer agents for raft polymerization in aqueous media UNIVERSITY OF SOUTHERN MISSISSIPPI 2003-10-16 — — US disclosed
US-20030191262-A1 Chain transfer agents for raft polymerization in aqueous media UNIVERSITY OF SOUTHERN MISSISSIPPI 2003-10-09 — — US disclosed
US-6610837-B1 Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization ISIS PHARMACEUTICALS, INC. 2003-08-26 — — US disclosed
WO-2003066685-A2 CHAIN TRANSFER AGENTS FOR RAFT POLYMERIZATION IN AQUEOUS MEDIA UNIVERSITY OF SOUTHERN MISSISSIPPI (US) 2003-08-14 — — WO disclosed
WO-2000055179-A1 NOVEL PHOSPHATE AND THIOPHOSPHATE PROTECTING GROUPS ISIS PHARMACEUTICALS, INC. (US) 2000-09-21 — — WO disclosed
US-6121437-A SYNTHESIS OF OLIGONUCLEOTIDES USING OLIGONUCLEOTIDES OR NUCLEOTIDES WITH PROTECTED INTERNUCLEOSIDIC PHOSPHORUS FUNCTIONALITIES WHICH CAN BE REMOVED UNDER MILD CONDITIONS AND PRODUCE NONTOXIC BY-PRODUCTS ISIS PHARMACEUTICALS, INC. (US) 2000-09-19 — — US disclosed
EP-0601520-A1 Trifluorothymidine derivatives, process for producing the same and anti-cancer agent containing the same MITSUI TOATSU CHEMICALS, Inc. (JP) 1994-06-15 — — EP disclosed
US-4870016-A CHANGING SOLUBILITY OF ENZYMES LEVESQUE GUY (FR) 1989-09-26 — — US disclosed
US-4518682-A CONTAINING COMPOUND WHICH GIVES FOGGING EFFECT FUJI PHOTO FILM CO., LTD. (JP) 1985-05-21 — — US disclosed
US-4078139-A Process for deoxygenating secondary alcohols SCHERING CORPORATION (US) 1978-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195310-A1 Chain transfer agents for raft polymerization in aqueous media TRRAP, NEFM, TMT1A CA12 1082/4885CA1 2002/4885CA2 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.